AbbVie Inc. Share Price & Technical Analysis
ABBV · $215.7 (+0.56%)
Healthcare / Drug Manufacturers - General
$215.7
+0.56%
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various ca…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
2% return in May, -4% avg return in past 3 year May month.
-7% return in 2026, 16% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -2% | 3% | -7% | -3% | 2% | – | – | – | – | – | – | – | -7% |
| 25 | 3% | 14% | 0% | -7% | -4% | 0% | 2% | 11% | 10% | -7% | 5% | 1% | 28% |
| 24 | 6% | 8% | 3% | -11% | -1% | 7% | 8% | 5% | 1% | 3% | -11% | -3% | 17% |
| 23 | -9% | 5% | 4% | -4% | -8% | 0% | 12% | -2% | 1% | -5% | 0% | 9% | 2% |
| 22 | 1% | 8% | 10% | -9% | 1% | 4% | -6% | -5% | 0% | 8% | 10% | 0% | 20% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Strong
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$368.92B
P/E ratio
101.86
52W high
$244.8
52W low
$181.7
Volume
39,74,116
Beta
0.30
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is AbbVie Inc. share price today?
- AbbVie Inc. (ABBV) last traded around $215.7 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ABBV have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ABBV. Download the app for real-time alerts.
- How can I analyze AbbVie Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.